Financial Analysis: Cellular Dynamics International (NASDAQ:ICEL) vs. Its Peers

Cellular Dynamics International (NASDAQ: ICEL) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Cellular Dynamics International to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

This table compares Cellular Dynamics International and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cellular Dynamics International N/A N/A -8.53
Cellular Dynamics International Competitors $217.40 million -$39.40 million -84.17

Cellular Dynamics International’s peers have higher revenue, but lower earnings than Cellular Dynamics International. Cellular Dynamics International is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cellular Dynamics International and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellular Dynamics International 0 0 0 0 N/A
Cellular Dynamics International Competitors 669 2531 6835 136 2.63

As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.47%. Given Cellular Dynamics International’s peers higher probable upside, analysts plainly believe Cellular Dynamics International has less favorable growth aspects than its peers.

Profitability

This table compares Cellular Dynamics International and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellular Dynamics International -88.12% -57.59% -38.09%
Cellular Dynamics International Competitors -4,447.10% -475.35% -42.90%

Institutional and Insider Ownership

47.4% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cellular Dynamics International Company Profile

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive News & Ratings for Cellular Dynamics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Dynamics International and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.